CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference

TUBINGEN, Germany, Dec. 21, 2015 /PRNewswire/ -- CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced that the company will present at the 34^th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will provide an overview of the company's business, industry-leading mRNA technology platform and clinical-stage development pipeline during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Dr. Hoerr will for the first time present data from the first-ever clinical proof-of-concept trial of an mRNA-based prophylactic vaccine.

2015 was a transformative year for CureVac, highlighted by the largest equity investment of the Gates Foundation completed in March and the company's recent $110M financing (completed November 2015), the publication of peer-reviewed studies validating its mRNA technology platform, and the establishment of collaborative agreements including those with IAVI (International AIDS Vaccine Initiative), the Bill & Melinda Gates Foundation and numerous vaccine-development projects.

In 2016 CureVac anticipates achieving multiple clinical and operational milestones, including the reporting of clinical data from its placebo controlled double blinded Phase IIb clinical trial of CV9104 in patients with prostate cancer, the start of construction of an industrial scale GMP production facility with 30 million dose/year capability, and the initiation of new clinical programs including those in collaboration with Boehringer Ingelheim and IAVI.

About CureVac AG
Founded in 2000 as a spin-off from the University of Tubingen in Germany, CureVac is a technology leader in the development of drugs that are based on Messenger RNA (mRNA). The company has more than 15 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

Since its inception, CureVac has received approximately $330 million (€300 million) in equity investments and entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year.

For more information, please visit www.curevac.com.

Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tubingen, Germany
T: +49 (0) 7071 9883 1756
[email protected]

Andrew Mielach, Vice President 
Tiberend Strategic Advisors, New York 
T: +1 212 375 2694
[email protected]

Ash Spiegelberg, Director
Brunswick Group, Dallas 
T: +1 214 205 6805
[email protected]

SOURCE CureVac

Related Links

http://www.curevac.com